| Grant ID | DP220030 |
| Awarded On | September 14, 2022 |
| Title | Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of IMSA101 in Combination with Radiotherapy and Checkpoint Inhibitors in Solid Tumor Malignancies |
| Program | Product Development Research |
| Award Mechanism | Texas Company Product Development Awards |
| Institution/Organization | ImmuneSensor Therapeutics Inc. |
| Principal Investigator/Program Director | Lijun Sun |
| Cancer Sites | Head and Neck, Kidney and Renal Pelvis, Lung and Bronchus |
| Contracted Amount | $16,154,562 |
| Lay Summary |
ImmuneSensor Therapeutics Inc. is a Dallas, Texas-based clinical stage biotechnology company founded on Dr. Zhijian Chen's CPRIT funded research at UTSW. The company is developing a new class of drug called STING agonist that activates the patient's immune system to fight cancers. Immunotherapy has revolutionized cancer therapy; however, inadequacy remains due to insufficiency in mobilizing and coordinating the immune system against the cancer. STING agonist can help overcome such insufficiency. ImmuneSensor's lead STING agonist, IMSA101 has shown in Phase 1 trial an excellent clinical safety profile and encouraging immune stimulatory activity. It is ready to advance into Phase 2 trials. Imm... |